Kelsea S McKay

Sep 26, 2024 | biorxiv.org | Lahari Basu |Myriam P Hoyeck |Lili Grieco-St-Pierre |Kelsea S McKay

AbstractCancer survivors have an increased risk of developing new-onset Type 2 diabetes compared to the general population. Moreover, patients treated with cisplatin, a commonly used chemotherapeutic agent, are more likely to develop metabolic syndrome and Type 2 diabetes compared to age- and sex-matched controls.